var data={"title":"Visceral leishmaniasis: Treatment","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Visceral leishmaniasis: Treatment</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/contributors\" class=\"contributor contributor_credentials\">Caryn Bern, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Visceral leishmaniasis (VL; also known as kala-azar) is caused by parasites of the <em>Leishmania donovani </em>complex [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1\" class=\"abstract_t\">1</a>]. These parasites may be divided taxonomically and geographically into two groups: <em>L. donovani</em> (South Asia and East Africa) and <em>L. infantum</em> (Mediterranean basin, western Asia from the Middle East to Pakistan, Brazil, and other parts of the New World) (<a href=\"image.htm?imageKey=ID%2F58861\" class=\"graphic graphic_table graphicRef58861 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/2,3\" class=\"abstract_t\">2,3</a>]. <em>L. chagasi</em> is synonymous with <em>L. infantum</em> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Issues related to treatment of VL will be reviewed here. Issues related to epidemiology, clinical manifestations, and prevention of visceral leishmaniasis are discussed separately, as are issues related to cutaneous leishmaniasis. (See related topics.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">GENERAL PRINCIPLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the absence of treatment, the case fatality rate of fully manifest clinical visceral leishmaniasis (VL, kala-azar) without treatment is &gt;90 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Mortality is often due to hemorrhagic or infectious complications. </p><p>Treatment consists of antileishmanial therapy; the main constraints on the choice of antileishmanial drug are cost and availability. Drug resistance must also be considered, especially for VL originating in the Indian subcontinent. Supportive therapy to address nutritional status, concomitant anemia, hemorrhagic complications, and secondary infections is also essential to optimize treatment outcomes [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/2,6\" class=\"abstract_t\">2,6</a>]. (See <a href=\"#H3\" class=\"local\">'Clinical approach'</a> below.)</p><p>Patients with VL should be evaluated for HIV coinfection; if found, HIV should be treated aggressively. In the absence of effective immune reconstitution, treatment response is poor in HIV-VL-coinfected patients [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7-9\" class=\"abstract_t\">7-9</a>]. (See <a href=\"#H13\" class=\"local\">'HIV coinfection'</a> below.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL APPROACH</span></p><p class=\"headingAnchor\" id=\"H4029820504\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Agents with efficacy against visceral leishmaniasis (VL) include amphotericin B, pentavalent antimonial drugs, <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> (a parenteral aminoglycoside), and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> (the first oral drug for treatment of VL) (<a href=\"image.htm?imageKey=ID%2F80899\" class=\"graphic graphic_table graphicRef80899 \">table 2</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> is the drug with the highest therapeutic efficacy and the most favorable safety profile; monotherapy (total dose 20 to 21 <span class=\"nowrap\">mg/kg;</span> see below for dosing schedules) with this agent is the preferred treatment in Europe, North America, and South America [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1,10-12\" class=\"abstract_t\">1,10-12</a>]. Conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> has high antileishmanial efficacy but is associated with high risk of renal toxicity and other side effects. Other lipid-associated amphotericin B formulations have toxicity profiles intermediate between liposomal and conventional amphotericin B, but efficacy data are limited [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pentavalent antimonial drugs, <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a> (SSG) and meglumine antimoniate, are still widely used; however, monotherapy with antimonial agents is no longer a first-line treatment for VL when other less toxic drugs are available [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10,13,14\" class=\"abstract_t\">10,13,14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two new drugs have been added to the armamentarium since 1999: <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10,13\" class=\"abstract_t\">10,13</a>]. Miltefosine was approved for use in adults by the US Food and Drug Administration (FDA) in March 2014 [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/15\" class=\"abstract_t\">15</a>]; paromomycin is not readily available in the United States.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">Pentamidine</a> isethionate was previously a second-line treatment but is rarely used due to suboptimal efficacy and toxicity (with particular risk of irreversible insulin-dependent diabetes mellitus) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"#H1083951617\" class=\"local\">'Secondary prophylaxis'</a> below.)</p><p/><p>Species identification usually is not critical to treatment decisions for VL (in contrast with cutaneous leishmaniasis). However, sensitivity to specific drugs varies by region and first-line treatment recommendations in major VL-endemic areas have diverged [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/17\" class=\"abstract_t\">17</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In India and Nepal, high-level resistance to antimonial drugs is common; in these regions, <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> and conventional or lipid-associated <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> have replaced antimonial drugs as first-line treatments over the past decade [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10,13,18,19\" class=\"abstract_t\">10,13,18,19</a>]. The national control programs in India, Bangladesh, and Nepal utilize single-dose <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (10 <span class=\"nowrap\">mg/kg</span> intravenous [IV] infusion) as the first-line treatment, with increasing impetus for a future transition to combination therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/17\" class=\"abstract_t\">17</a>]. In South Asia, <em>L. donovani</em> responds to lower doses of liposomal amphotericin B and <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> than <em>L. infantum</em> or East African <em>L. donovani</em> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11,20\" class=\"abstract_t\">11,20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In East Africa, first-line therapy consists of combination treatment <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a> and <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> for 17 days; the efficacy of <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>, <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>, and paromomycin monotherapy are unacceptably low [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/21-24\" class=\"abstract_t\">21-24</a>].</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Special circumstances</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">HIV coinfection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Visceral leishmaniasis and human immunodeficiency virus (HIV) both target the cellular immune response and exert synergistically detrimental effects [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7,25-27\" class=\"abstract_t\">7,25-27</a>].</p><p>Patients with HIV coinfection may have severe <span class=\"nowrap\">and/or</span> atypical clinical presentations and may respond poorly to treatment in the absence of immune reconstitution [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7-9\" class=\"abstract_t\">7-9</a>]. The highest cumulative number of HIV-VL coinfections have been reported from Spain, but this is presumed to reflect better reporting from this region compared with Africa or Asia [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7,28\" class=\"abstract_t\">7,28</a>]. The disease burden is greatest for the Horn of Africa and is increasing in the Indian subcontinent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7,28\" class=\"abstract_t\">7,28</a>]. In treatment facilities on the Ethiopia-Sudan border, more than 30 percent of VL patients are coinfected with HIV [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/29\" class=\"abstract_t\">29</a>]. In one treatment facility in Bihar, India, the focus with the highest burden of VL in the world, the prevalence of HIV coinfection in VL patients rose from 0.9 to 2.2 percent between 2000 and 2006 [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H289398907\"><span class=\"h4\">Antiparasitic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> is the treatment of choice for patients with HIV and VL coinfection [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1,9,11,30\" class=\"abstract_t\">1,9,11,30</a>]. Liposomal and lipid complex preparations are significantly better tolerated than conventional amphotericin B or pentavalent antimony, although these agents have comparable efficacy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/12,31-36\" class=\"abstract_t\">12,31-36</a>]. In VL-endemic areas in Asia, Africa, and Latin America, the use of liposomal amphotericin B has been constrained by the high cost of the drug, but the drug is available under a donation program [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H518134611\" class=\"local\">'Liposomal'</a> below.)</p><p>Patients with HIV-VL coinfection require higher total doses of amphotericin B than VL patients without HIV. Because of greater tolerability, higher daily dosing is recommended for liposomal or lipid complex preparations than conventional amphotericin B [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11,37\" class=\"abstract_t\">11,37</a>]. Molecular data suggest that parasite clearance is more rapid and complete for <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> than for lipid emulsion preparations [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/38\" class=\"abstract_t\">38</a>]. Dosing regimens are summarized in the table (<a href=\"image.htm?imageKey=ID%2F80899\" class=\"graphic graphic_table graphicRef80899 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11,31,33,34,37,39\" class=\"abstract_t\">11,31,33,34,37,39</a>].</p><p>Data on the use of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> among HIV-VL&ndash;coinfected patients are limited; in one series including 25 patients, the initial cure rate was 64 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/40\" class=\"abstract_t\">40</a>]. Among 199 Ethiopian VL patients with a high prevalence of HIV-coinfection treated with miltefosine or pentavalent antimony, miltefosine was associated with a lower cure rate at 30 days (70 versus 81 percent) but more favorable mortality rate (6 versus 12 percent) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/41\" class=\"abstract_t\">41</a>]. Among 25 patients with HIV-VL coinfection in Europe, meglumine antimoniate treatment was associated with adverse effects in more than half of cases, including acute pancreatitis, acute renal failure, and leukopenia [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/42\" class=\"abstract_t\">42</a>].</p><p>There are no data addressing the efficacy of <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> monotherapy for treatment of VL in HIV-coinfected patients.</p><p>Data on combination regimens for HIV-VL coinfected patients are limited. Patients with refractory VL or multiple relapses may be offered a combination of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> plus liposomal amphotericin or miltefosine plus <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1,7,43\" class=\"abstract_t\">1,7,43</a>].</p><p>One retrospective study including 102 HIV-VL&ndash;coinfected patients in India noted that a regimen of liposomal amphotericin (30 <span class=\"nowrap\">mg/kg</span> total dose; 5 <span class=\"nowrap\">mg/kg</span> every other day for 14 days) and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> (50 mg twice daily if &ge;25 kg; 50 mg once daily if 12 to 24 kg) was well tolerated and at least as effective as <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> monotherapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/44\" class=\"abstract_t\">44</a>]. The combination regimen was associated with 12-month mortality and relapse rates of 11 and 6 percent, respectively; liposomal amphotericin B monotherapy (20 to 25 <span class=\"nowrap\">mg/kg</span> total dose) was associated with 12-month mortality and relapse rates of 8.7 and 16 percent, respectively [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/45\" class=\"abstract_t\">45</a>]. Patients not on antiretroviral treatment (ART) prior to VL treatment were significantly more likely to die than those already on ART (adjusted hazard ratio 8.0; 95% CI 2.0-32.5; p &lt;0.01). A retrospective analysis of data from 111 HIV-VL&ndash;coinfected patients in Ethiopia also suggested better outcomes for combination liposomal amphotericin B total dose 30 <span class=\"nowrap\">mg/kg</span> in combination with miltefosine 2.5 <span class=\"nowrap\">mg/kg</span> per day for 28 days than historically seen with monotherapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H487906761\"><span class=\"h4\">Antiretroviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antiretroviral therapy should be initiated or optimized as soon as the patient is sufficiently able to tolerate it (eg, either during or soon after the initial course of therapy for VL) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1\" class=\"abstract_t\">1</a>].</p><p>VL that becomes clinically manifest or worsens after initiation of ART should be treated with antileishmanial (and, if indicated, corticosteroid) therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Among European patients with HIV-VL coinfection not taking ART, the 12-month risk of VL relapse after initial antileishmanial treatment was 90 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/47,48\" class=\"abstract_t\">47,48</a>]. ART has significantly improved the survival of HIV-VL&ndash;coinfected patients and can decrease the likelihood of relapse after antileishmanial therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/29,49-51\" class=\"abstract_t\">29,49-51</a>]. In one study including 356 Ethiopian patients, ART decreased VL relapse rates by approximately 50 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/29\" class=\"abstract_t\">29</a>].</p><p>In another study including 146 HIV-VL coinfected patients in Ethiopia, the cumulative incidence of relapse at 12 and 24 months was 26 and 35 percent, respectively [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/52\" class=\"abstract_t\">52</a>]. Antiretroviral therapy was associated with significant protection (adjusted hazard ratio [aHR] 0.39 [95% CI 0.17-0.86] for ART started during VL treatment; aHR 0.22 [95% CI 0.10-0.52] for ART started prior to VL treatment), and high splenic parasite load was associated with elevated risk.</p><p>Antiretroviral therapy should be managed as discussed in detail separately [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">&quot;Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1083951617\"><span class=\"h4\">Secondary prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Secondary prophylaxis is warranted to decrease the risk for posttreatment relapse of VL in patients with <span class=\"nowrap\">HIV/AIDS-associated</span> immunosuppression, particularly in the setting of CD4+ counts &lt;200 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/47-49,53\" class=\"abstract_t\">47-49,53</a>]. VL relapses can occur even with CD4+ counts &gt;350 <span class=\"nowrap\">cells/microL,</span> leading some experts to advise against discontinuation of secondary prophylaxis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/29,54,55\" class=\"abstract_t\">29,54,55</a>]. Others favor considering discontinuation if there are no signs of VL and the CD4+ count has remained &gt;200 <span class=\"nowrap\">cells/microL</span> for at least six months [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7\" class=\"abstract_t\">7</a>]. For HIV-VL&ndash;coinfected patients with multiple relapses, compassionate use of combination regimens can be considered (see <a href=\"#H2387204249\" class=\"local\">'Combination therapy'</a> below).</p><p>The optimal regimen for secondary prophylaxis is uncertain; possibilities include amphotericin B, <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a>, and <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a>. One randomized trial demonstrated lower relapse rates at one year with intermittent administration of <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> (3 <span class=\"nowrap\">mg/kg</span> every 21 days) compared with no prophylaxis (50 versus 78 percent, respectively) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/53\" class=\"abstract_t\">53</a>]. Decreased relapse rates have also been observed in retrospective studies of prophylaxis with monthly sodium stibogluconate (SSG; 850 mg) or <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (200 to 350 mg) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/48,49\" class=\"abstract_t\">48,49</a>]. In a trial including ART-treated patients in Ethiopia who received monthly infusions of 4 <span class=\"nowrap\">mg/kg</span> pentamidine-isethionate, the probability of 12-month relapse-free survival was 71 percent, comparing favorably with historical controls [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/56\" class=\"abstract_t\">56</a>].</p><p class=\"headingAnchor\" id=\"H2377420657\"><span class=\"h3\">Other immunocompromised hosts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of choice for VL in patients with solid organ transplant, malignancy, or other forms of immunosuppression is liposomal amphotericin [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1\" class=\"abstract_t\">1</a>]. Whenever, possible, doses of immunosuppressive drugs should be decreased in patients with VL during antileishmanial therapy.</p><p>Secondary prophylaxis is not required for initial management of non&ndash;HIV-infected immunosuppressed patients who have not manifested a relapse. In addition, patients with asymptomatic VL warrant close monitoring but do not require preemptive treatment or primary prophylaxis.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VL infection in the setting of pregnancy has been associated with congenital infection and fetal death [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/57\" class=\"abstract_t\">57</a>]. <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> is the drug of choice for treatment of VL in pregnancy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/58,59\" class=\"abstract_t\">58,59</a>]. Alternative choices include <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> and pentavalent antimony. Good clinical and pregnancy outcomes have been reported for five pregnant women treated with liposomal amphotericin B and three cases treated with meglumine antimoniate [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/58-60\" class=\"abstract_t\">58-60</a>].</p><p><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine</a> is contraindicated in pregnancy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Post kala-azar dermal leishmaniasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of post kala-azar dermal leishmaniasis (PKDL) requires prolonged treatment; the optimal approach is uncertain, and clinical trial data are limited.</p><p>In the Indian subcontinent, the first-line treatment for PKDL consists of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> 2.5 <span class=\"nowrap\">mg/kg/day</span> for 12 weeks. In one trial including 35 patients treated with 100 <span class=\"nowrap\">mg/day</span> for 8 or 12 weeks, intention-to-treat cure rates were 76 and 78 percent, respectively; per-protocol cure rates were 81 and 93 percent, respectively [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/61\" class=\"abstract_t\">61</a>]. However, data suggest some PKDL patients may require up to 16 weeks of miltefosine and that relapse rates among those treated for 12 weeks may be increasing in northern India due to selection for resistant parasites over the prolonged treatment course [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/62,63\" class=\"abstract_t\">62,63</a>]. The traditional approach to PKDL in India consists of SSG (20 <span class=\"nowrap\">mg/kg)</span> for two to four months [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/64\" class=\"abstract_t\">64</a>]. In an Indian trial performed in 1987 including 108 patients with PKDL, cure rates for those treated for four months with daily injections of 10 <span class=\"nowrap\">mg/kg,</span> 15 <span class=\"nowrap\">mg/kg,</span> or 20 <span class=\"nowrap\">mg/kg</span> were 50, 67, and 92 percent, respectively [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/65\" class=\"abstract_t\">65</a>].</p><p>In Africa, conventional treatment for PKDL consists of <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a> 20 <span class=\"nowrap\">mg/kg/day</span> for 30 to 60 days (substantially shorter than for Indian PKDL).</p><p><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> may be superior to antimony treatment in terms of speed of response and cure [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/66\" class=\"abstract_t\">66</a>]. This was evaluated in a study of 22 patients in India in 1997 treated with amphotericin B deoxycholate infusion (1 <span class=\"nowrap\">mg/kg/day</span> for 20 days with intervening 20-day drug-free intervals) or SSG intramuscular injection (20 <span class=\"nowrap\">mg/kg</span> day for 20 days with intervening 20-day drug-free intervals) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/66\" class=\"abstract_t\">66</a>]. Cure rates for the amphotericin arm and the SSG arm were 100 percent (11 of 11) and 64 percent (7 of 11), respectively. The decrease in the cure rate with SSG from 1987 to 1997 may also reflect the increasing SSG resistance in Bihar observed over that period of time [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Subsequent studies have focused on the use of <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> and combination regimens for PKDL. However, the optimal regimen is still uncertain and probably will be found to differ by geographic region. A trial that included 12 Sudanese patients with PKDL suggested that prolonged treatment with liposomal amphotericin B (2.5 <span class=\"nowrap\">mg/kg</span> for 20 days) may succeed in curing PKDL unresponsive to SSG [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/67\" class=\"abstract_t\">67</a>]. <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Sodium stibogluconate</a> (30 <span class=\"nowrap\">mg/kg/day</span> for a minimum of 17 days) plus <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> (15 mg <span class=\"nowrap\">sulphate/kg/day</span> for 17 days) may have higher efficacy than sodium stibogluconate alone [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H402494588\"><span class=\"h2\">Assessing response to treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Response to treatment is generally assessed clinically, based on resolution of fever, which generally occurs within one to two weeks, decrease in spleen size within a month of treatment initiation, and weight gain. Patients with clinical response need not undergo additional testing for parasitologic confirmation but should be followed clinically for at least 12 months and instructed to return if symptoms recur [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1\" class=\"abstract_t\">1</a>]. In immunocompetent patients, most relapses occur within 6 to 12 months of completion of treatment, although relapses were seen up to 18 months post-treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/69\" class=\"abstract_t\">69</a>]. Immunocompromised patients should be followed for a minimum of one year (ideally, lifelong or until effective immune reconstitution) to assess for symptoms of posttreatment relapse.</p><p>In patients whose clinical response is equivocal (eg, no decrease in spleen size, continued fever) or are suspected to have relapse, bone marrow or splenic aspirate should be performed to confirm the diagnosis of VL <span class=\"nowrap\">and/or</span> to evaluate for alternative diagnoses.</p><p>Serologic tests are not useful tests of cure, as they remain positive for months to years after treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/70,71\" class=\"abstract_t\">70,71</a>]. The urine KAtex assay detects parasite antigen in urine and becomes negative more rapidly than serologic assays but has poor sensitivity for diagnosis and is not widely available [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H2154256700\"><span class=\"h2\">Adjusting therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunocompetent patients with VL who do not respond to initial therapy with liposomal amphotericin should be treated with an alternative drug, with a higher dose or longer course of liposomal amphotericin or with a combination regimen. No trial data are available to determine the optimal regimen [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Immunocompetent patients with VL who do not respond to initial therapy with <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> or a pentavalent antimonial compound should be treated with liposomal amphotericin or an alternative drug if liposomal amphotericin is not available. Immunocompetent patients with VL who respond to initial therapy but subsequently relapse should be treated with an alternative or another potentially longer course of therapy with the initial drug. If liposomal amphotericin was the drug used for initial therapy, use of a higher total dose (eg, 30 to 40 <span class=\"nowrap\">mg/kg)</span> may be warranted.</p><p>Immunocompromised patients with VL who do not respond to initial therapy can be managed by retreatment with liposomal amphotericin at the same or a higher total dose.</p><p class=\"headingAnchor\" id=\"H3201726250\"><span class=\"h1\">THERAPEUTIC AGENTS</span></p><p class=\"headingAnchor\" id=\"H4029043717\"><span class=\"h2\">Amphotericin B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> binds to parasite ergosterol precursors such as lanosterol, causing disruption of the parasite membrane [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H518134611\"><span class=\"h3\">Liposomal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> (AmBisome) consists of amphotericin B packaged with cholesterol and other phospholipids within a small unilamellar liposome [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/74\" class=\"abstract_t\">74</a>]. The characteristics of this specialized formulation facilitate improved antimicrobial efficacy with reduced systemic toxicity. The liposomal drug formulation has improved stability in blood, macrophages, and tissues, permitting more effective tissue penetration with sustained tissue drug levels, especially in the liver and spleen. This formulation has increased affinity for ergosterol and its precursors with excellent antimicrobial efficacy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/75\" class=\"abstract_t\">75</a>]. In addition, the presence of cholesterol in the formulation minimizes interaction with mammalian cell membranes, thereby reducing toxicity [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/75\" class=\"abstract_t\">75</a>].</p><p><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> is the only drug with US Food and Drug Administration (FDA) approval for treatment of visceral leishmaniasis (VL) in the United States [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/37\" class=\"abstract_t\">37</a>]. Four European trials including a total of 348 patients treated with total cumulative doses &gt;18 <span class=\"nowrap\">mg/kg</span> demonstrated cure rates of 98 to 100 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/31,76-78\" class=\"abstract_t\">31,76-78</a>]. Two African studies including a total of 74 patients treated with total doses ranging from 10 to 24 <span class=\"nowrap\">mg/kg</span> demonstrated cure rates of 88 to 100 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/79,80\" class=\"abstract_t\">79,80</a>]. Three Indian trials including a total of 144 patients treated with total doses of 14 to 20 <span class=\"nowrap\">mg/kg</span> demonstrated cure rates of 96 to 100 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/81-83\" class=\"abstract_t\">81-83</a>]. An expert panel convened by the World Health Organization (WHO) in 2005 concluded that a total cumulative dose of 20 <span class=\"nowrap\">mg/kg</span> is adequate to achieve high cure rates in immunocompetent VL patients in all regions of the world, regardless of the specific dosing schedule [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11\" class=\"abstract_t\">11</a>].</p><p>The wide variation in successful dosing schedules may reflect the fact that the drug accumulates in viscera and the active drug is then slowly released. Pharmacokinetic studies suggest that optimal tissue levels may be achieved if the initial dose is at least 5 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/74\" class=\"abstract_t\">74</a>], although the FDA recommends 3 <span class=\"nowrap\">mg/kg</span> on days 1 to 5, 14, and 21 for a total dose of 21 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/37\" class=\"abstract_t\">37</a>]. In New Zealand, the recommended regimen is 1 to 1.5 <span class=\"nowrap\">mg/kg</span> for 21 days or 3 <span class=\"nowrap\">mg/kg</span> for 10 days. In Italy, the standard regimen consists of 3 <span class=\"nowrap\">mg/kg</span> days 1 to 5 and 10 for a total dose of 18 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/84\" class=\"abstract_t\">84</a>]. Many European pediatricians favor a regimen of 10 <span class=\"nowrap\">mg/kg/day</span> on two consecutive days, obviating the need for longer hospitalization [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/85\" class=\"abstract_t\">85</a>].</p><p>In VL-endemic areas in Asia, Africa, and Latin America, the use of <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> has been constrained by the high cost of the drug [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11\" class=\"abstract_t\">11</a>]. Liposomal amphotericin B is available through the World Health Organization at preferential pricing for non-profit and public sectors in low- and selected moderate-income VL-endemic countries; nonetheless, the total cost of a treatment course is substantially higher than generic SSG or conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a>. A large donation by the manufacturer has further increased access to liposomal amphotericin B in several highly endemic countries [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/86\" class=\"abstract_t\">86</a>].</p><p>Because cost is the limiting factor for use of <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>, many different regimens have been evaluated in India in an attempt to find the lowest total dose with acceptable efficacy. Among 203 patients in one study, a single dose of 7.5 <span class=\"nowrap\">mg/kg</span> gave a 90 percent cure rate at six months [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/87\" class=\"abstract_t\">87</a>]. Among 84 patients with VL in another study, total doses of 10 to 15 <span class=\"nowrap\">mg/kg</span> in various schedules gave cure rates &gt;95 percent, while a single dose of 3.75 <span class=\"nowrap\">mg/kg</span> led to a cure rate of 89 percent in a limited number of patients [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/81\" class=\"abstract_t\">81</a>]. A third trial including 304 patients compared a single dose of liposomal amphotericin B (10 <span class=\"nowrap\">mg/kg)</span> with conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (15 <span class=\"nowrap\">mg/kg</span> total dose; 1 <span class=\"nowrap\">mg/kg</span> every other day for 15 doses); efficacy was equivalent (96 percent) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/88\" class=\"abstract_t\">88</a>]. Single-dose therapy (10 <span class=\"nowrap\">mg/kg)</span> has been approved as first-line treatment in Bangladesh and is under consideration in the Indian VL control program for treatment in the epidemic settings facing these countries [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/89,90\" class=\"abstract_t\">89,90</a>]. However, the use of 10 <span class=\"nowrap\">mg/kg</span> as a single infusion carries a risk of severe hypotension [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/90\" class=\"abstract_t\">90</a>], and this total dose is clearly insufficient outside of the Indian subcontinent. For settings other than those covered by leishmaniasis treatment programs in the Indian subcontinent, the FDA-approved regimen outlined above is preferred because of the better safety profile and high efficacy.</p><p><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B</a> causes substantially less toxicity than conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> because of differences in cell penetration, pharmacokinetic properties, and interactions with lipoproteins and host cells [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73\" class=\"abstract_t\">73</a>]. Infusion-related reactions are less common and less severe than with conventional amphotericin B or <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/12\" class=\"abstract_t\">12</a>]. Although transient rises in creatinine can occur, acute and chronic toxicity from liposomal amphotericin B is low even when 15 <span class=\"nowrap\">mg/kg</span> is administered as a single dose [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/91\" class=\"abstract_t\">91</a>].</p><p>Clinical resistance to <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> appears to be rare, although resistant parasites have been generated in culture [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H378131154\"><span class=\"h3\">Conventional</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> should be administered as a slow intravenous infusion over four hours. Effective regimens include 0.75 to 1.0 <span class=\"nowrap\">mg/kg</span> daily for 15 to 20 days or 0.75 to 1.0 <span class=\"nowrap\">mg/kg</span> every other day for 30 to 40 days. Alternate day dosing and pretreatment saline loading may decrease risk of renal toxicity and other adverse effects [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/92\" class=\"abstract_t\">92</a>].</p><p>Renal function should be monitored carefully; amphotericin B can cause renal abnormalities such as distal renal tubular acidosis, nephrogenic diabetes insipidus, and renal potassium wasting. These are usually reversible with discontinuation of the drug, although dose-related acute renal insufficiency can be progressive and incompletely reversible.</p><p>Fever and rigors are also common, especially at the beginning of infusion; pretreatment antipyretics may decrease severity. Other adverse effects include malaise, anorexia, bone marrow suppression, myalgia, arthralgia, and rash.</p><p class=\"headingAnchor\" id=\"H1386914187\"><span class=\"h3\">Other preparations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pharmacokinetics and in vitro and in vivo activity profiles differ with different lipid delivery vehicles, although the mechanism of action for all formulations of amphotericin B is the same [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Clinical trial data are limited for lipid associated amphotericin preparations other than <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>, and optimum dosing schedules are not established. For amphotericin B colloidal dispersion, studies in Italy and India have demonstrated efficacy &gt;95 percent for regimens totaling 7.5 to 15 <span class=\"nowrap\">mg/kg</span> over six to seven days [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/93,94\" class=\"abstract_t\">93,94</a>]. In India, efficacy has been demonstrated for <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> (short courses totaling 5 to 15 <span class=\"nowrap\">mg/kg)</span> and amphotericin B lipid emulsion (15 <span class=\"nowrap\">mg/kg)</span> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/12,95\" class=\"abstract_t\">12,95</a>].</p><p><a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">Amphotericin B lipid complex</a> has a side effect profile intermediate between <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> and conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/12,82\" class=\"abstract_t\">12,82</a>]. At higher doses, amphotericin B colloidal dispersion has been associated with severe back pain [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/94\" class=\"abstract_t\">94</a>].</p><p class=\"headingAnchor\" id=\"H337115261\"><span class=\"h2\">Pentavalent antimonial compounds</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pentavalent antimonial drugs have been used for the treatment of VL since the 1940s. <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Sodium stibogluconate</a> (brand name Pentostam [GSK]; also generic versions from many manufacturers) and meglumine antimoniate (brand name Glucantime [Aventis]) remain the most widely used antileishmanial agents [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/96\" class=\"abstract_t\">96</a>].</p><p>There are no trials comparing the efficacy and toxicity of SSG with meglumine antimoniate for VL; the two drugs are considered largely interchangeable and the choice between them is governed by availability and historical usage patterns [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10\" class=\"abstract_t\">10</a>]. There have been several double-blind controlled comparisons of Pentostam and generic SSG from one specific manufacturer demonstrating equivalent efficacy and toxicity profiles [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/41,97,98\" class=\"abstract_t\">41,97,98</a>]. However, generic SSG from other manufacturers has not been tested, and the efficacy and toxicity of these preparations are considered unproven [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10\" class=\"abstract_t\">10</a>]. In India and Nepal, clusters of patients with severe toxicity and fatal outcomes have raised concern about the use of untested generic SSG [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/99,100\" class=\"abstract_t\">99,100</a>].</p><p>The mechanism of action of pentavalent antimonial drugs is uncertain; in vivo conversion to trivalent antimony compounds may be involved in both antileishmanial activity and drug toxicity [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/101\" class=\"abstract_t\">101</a>]. Other studies suggest that antileishmanial activity may occur via inhibition of parasite ADP phosphorylation, DNA I topoisomerase, <span class=\"nowrap\">and/or</span> trypanothione reductase [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73,102\" class=\"abstract_t\">73,102</a>].</p><p>Toxicity is usually related to the cumulative dose. The most serious adverse effects are cardiotoxicity and clinical pancreatitis, either of which can lead to death. Other side effects are frequent and include myalgia and arthralgia, nausea, vomiting, abdominal pain, headache, fatigue, rash, electrocardiographic abnormalities, elevated liver function tests, elevated lipase and amylase levels, and decreased hemoglobin, white blood cell, and platelet counts [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/103\" class=\"abstract_t\">103</a>].</p><p>Antimony can lead to nonspecific EKG changes, including flattening or inversion of the T waves [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/104\" class=\"abstract_t\">104</a>]. Prolongation of the corrected QT interval (measured QT interval divided by the square root of the preceding RR interval) to &gt;0.5 seconds or development of T wave inversion with concave ST segments are considered signs of serious cardiotoxicity and should prompt immediate cessation of treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/103\" class=\"abstract_t\">103</a>]. Preexisting cardiac disease is thought to increase the risk of cardiotoxicity and is a contraindication to use of antimonial drugs.</p><p>The standard dosing regimen consists of 20 <span class=\"nowrap\">mg/kg/day</span> of antimony for 28 to 30 days [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/103\" class=\"abstract_t\">103</a>]. Administration is intravenous or intramuscular. Intramuscular injections are frequently used in regions with limited health infrastructure but are very painful as the volume is large and the compound is a tissue irritant [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/96\" class=\"abstract_t\">96</a>]. Sterile abscesses can result from intramuscular injection and phlebitis is a common complication of intravenous administration.</p><p>Prior to and during therapy, clinical monitoring as well as electrocardiogram (EKG), complete blood count, creatinine, transaminase, lipase, and amylase levels should be performed weekly. Asymptomatic elevations of amylase <span class=\"nowrap\">and/or</span> lipase levels occur in the majority of patients and do not require cessation of therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/105\" class=\"abstract_t\">105</a>]. However, clinical pancreatitis is an indication for suspending treatment, as are EKG findings as described above.</p><p>Accurate in vitro testing for antimonial resistance requires the use of amastigotes in a macrophage cellular system (not promastigote-based assays) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/106\" class=\"abstract_t\">106</a>]. High-level resistance to antimonial drugs is common in Bihar State, India, especially north of the river Ganges, and in southeastern Nepal [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/18,19,107\" class=\"abstract_t\">18,19,107</a>]. In these regions, conventional <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> has replaced SSG as the first-line treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10,13,18,19\" class=\"abstract_t\">10,13,18,19</a>]. Outside of these regions, efficacy of antimonial drugs is generally &gt;95 percent.</p><p>Pentavalent antimonial compounds are not licensed in the United States, but Pentostam is available under an investigational new drug (IND) protocol from the United States Centers for Disease Control and Prevention (CDC) Drug Service for civilians and the Walter Reed Army Medical Center for United States military personnel. Consultations about diagnostic testing, management, and drug requests should be addressed to the Division of Parasitic Diseases Public Inquiries line (404-718-4745; email parasites@cdc.gov), CDC Drug Service (404-639-3670), or for emergencies outside of business hours, CDC Emergency Operations Center (770-488-7100).</p><p class=\"headingAnchor\" id=\"H2348435053\"><span class=\"h2\">Miltefosine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine</a> is the only oral agent for treatment of VL. It was approved by the US Food and Drug Administration in March 2014 for treatment of VL caused by <em>L. donovani </em>in adults and adolescents who weigh at least 30 kg [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/15\" class=\"abstract_t\">15</a>]. The drug is available in 50 mg capsules. The treatment regimen approved by the FDA is based on patient weight: for patients 30 to 44 kg, the approved regimen consists of 50 mg twice daily for 28 consecutive days; for patients &ge;45 kg, the approved regimen consists of 50 mg three times daily for 28 consecutive days [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/108\" class=\"abstract_t\">108</a>]. The use of miltefosine to treat VL caused by <em>L. infantum</em> or VL in children who weigh less than 30 kg is considered off-label use. </p><p>The mechanism of action of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> is not fully understood. The drug is a phosphocholine analogue thought to interfere with cell-signaling pathways, and there is some evidence that it targets parasite lipid biosynthetic enzymes [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73\" class=\"abstract_t\">73</a>].</p><p><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine</a> is an effective drug for treatment of VL. Efficacy data are strongest for the Indian subcontinent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/43\" class=\"abstract_t\">43</a>]. In a study including 398 patients with VL in India, 299 received treatment with miltefosine (50 <span class=\"nowrap\">mg/day</span> if &lt;25 kg and 100 <span class=\"nowrap\">mg/day</span> if &gt;25 kg) and 99 received treatment with conventional amphotericin deoxycholate (1 <span class=\"nowrap\">mg/kg</span> every other day; total 15 infusions); cure rates at six months were 94 and 97 percent, respectively [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/109\" class=\"abstract_t\">109</a>]. Among Indian children, miltefosine was safe and approximately 90 percent effective at six months [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/110\" class=\"abstract_t\">110</a>]. Among 1132 adult and pediatric VL patients in northern India, six-month cure rates were 82 percent by intention to treat analysis and 94 percent by per protocol analysis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/111\" class=\"abstract_t\">111</a>]. However, after a decade of use in the Indian subcontinent, substantially higher failure rates are being reported. Data from longer follow-up studies have suggested that failure rates may reach 10 percent at 6 months and 20 percent at 12 months [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/112,113\" class=\"abstract_t\">112,113</a>]. Published efficacy data are lacking in East Africa, the Mediterranean, and South America [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/43\" class=\"abstract_t\">43</a>].</p><p>The standard regimen is 2.5 <span class=\"nowrap\">mg/kg/day</span> orally for 28 days. <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine</a> is teratogenic in experimental models; if miltefosine therapy is planned for women of reproductive age, a negative pregnancy test and effective contraception during and for at least two months after therapy are required. Pharmacokinetic data suggest that current dosing regimens may result in suboptimal blood levels, especially in children, and that allometric dosing may be preferable [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/114,115\" class=\"abstract_t\">114,115</a>].</p><p>Vomiting may occur in up to 65 percent of patients and diarrhea in 5 to 20 percent of patients, but these adverse effects rarely require suspension of treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/113\" class=\"abstract_t\">113</a>]. Transaminase elevations occur in 15 to 30 percent of patients, which may require suspension of therapy if severe [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/116\" class=\"abstract_t\">116</a>]. If the patient cannot tolerate <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> due to side effects, an alternative drug should be used.</p><p>The long half-life of <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> and the potential for poor compliance with oral therapy administered without clinician supervision has raised concern regarding potential for emergence of resistance. Laboratory-confirmed resistance to miltefosine has not been reported, although clinical failure rates of 8 to 30 percent have been reported in miltefosine treatment programs (compared with 3 to 4 percent in phase III trials) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/112,113,117\" class=\"abstract_t\">112,113,117</a>]. Relapse of VL following miltefosine treatment has been described in 3 to 11 percent of patients treated in clinical trials with at least six months of follow-up; such patients usually respond well to amphotericin B rescue therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/113,118\" class=\"abstract_t\">113,118</a>].</p><p class=\"headingAnchor\" id=\"H2940407862\"><span class=\"h2\">Paromomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">Paromomycin</a> (aminosidine) is an aminoglycoside antibiotic with activity against <em>Leishmania</em> as well as bacteria and some enteric protozoa. It binds the 30S ribosomal subunit, causing impaired parasite protein synthesis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/119\" class=\"abstract_t\">119</a>]. Parenteral paromomycin was used as an antibiotic until the 1980s when the introduction of newer antibiotics led to cessation of its manufacture. Topical and oral forms of paromomycin have been used for treatment of cutaneous leishmaniasis and intestinal amebiasis, respectively, but availability of these forms in the United States is limited. The parenteral form has received FDA Orphan Drug Status but is not currently available in the United States. Injectable paromomycin is produced in India (Glanda Pharma, Hyderabad) for the non-profit sector [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/119\" class=\"abstract_t\">119</a>].</p><p>Trials conducted in India have demonstrated good efficacy for doses ranging from 12 to 20 <span class=\"nowrap\">mg/kg/day</span> (intramuscular or intravenous administration) for 21 to 28 days (88 to 95 percent) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/120-122\" class=\"abstract_t\">120-122</a>]. In India, the recommended dosing schedule for <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> monotherapy is 15 <span class=\"nowrap\">mg/kg/day</span> (equivalent to 11 <span class=\"nowrap\">mg/kg/day</span> paromomycin base) for 21 days [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/121\" class=\"abstract_t\">121</a>].</p><p>Parasite susceptibility to <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> appears to be geographically variable. In East Africa, the efficacy of paromomycin monotherapy with the dosing range evaluated in India was &lt;90 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/123,124\" class=\"abstract_t\">123,124</a>]. Clinical trials are currently underway to determine the optimum paromomycin dosing schedule for African VL. Some nongovernmental organizations use paromomycin in combination with antimonial therapy, but optimized dosing schedules have not yet been determined in controlled trials [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/96,124\" class=\"abstract_t\">96,124</a>]. (See <a href=\"#H2387204249\" class=\"local\">'Combination therapy'</a> below.)</p><p>Adverse effects are uncommon; they include elevated liver function enzymes (&ge;3 times the upper limit of normal in 6 percent of patients), reversible ototoxicity (2 percent), and renal insufficiency (1 percent) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/121\" class=\"abstract_t\">121</a>].</p><p>Acquisition of resistance during therapy is a theoretical risk (since resistance can be induced in vitro), although thus far no clinically acquired resistance has been reported [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/125\" class=\"abstract_t\">125</a>]. Given the parenteral administration and relatively short half-life, the risk of inducing <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> resistance is likely lower than for <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a>.</p><p class=\"headingAnchor\" id=\"H2387204249\"><span class=\"h2\">Combination therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a broad consensus among experts that antileishmanial therapy in endemic regions should move toward combination drug regimens to (1) protect the limited armamentarium of antileishmanial agents from development of acquired resistance, and (2) establish shorter treatment courses with high efficacy to improve compliance and decrease treatment costs [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/96,126\" class=\"abstract_t\">96,126</a>]. However, published data are sparse and recommendations for specific combination regimens do not yet exist [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Several small trials or observational studies of <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> (12 to 18 <span class=\"nowrap\">mg/kg/day)</span> combined with SSG (20 <span class=\"nowrap\">mg/kg/day)</span> have demonstrated good parasitological response rates for dosing schedules of 17 to 21 days [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/122-124,127\" class=\"abstract_t\">122-124,127</a>]. In a dose-finding study in India, regimens that combined single dose liposomal amphotericin (5 <span class=\"nowrap\">mg/kg)</span> with <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> (100 mg daily) for 7, 10, or 14 days showed efficacy rates of 96 to 98 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/128\" class=\"abstract_t\">128</a>].</p><p>A subsequent trial among 634 patients in India with nonsevere VL demonstrated 97 to 98 percent efficacy for each of three combination regimens: single intravenous infusion of liposomal amphotericin (5 <span class=\"nowrap\">mg/kg)</span> plus <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> (50 mg per day for seven days), single intravenous infusion of liposomal amphotericin (5 <span class=\"nowrap\">mg/kg)</span> plus intramuscular <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> (11 <span class=\"nowrap\">mg/kg/day</span> for 10 days), and miltefosine (50 mg per day for 10 days) plus intramuscular paromomycin (11 <span class=\"nowrap\">mg/kg/day</span> for 10 days) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/129\" class=\"abstract_t\">129</a>]. </p><p><a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Sodium stibogluconate</a> plus <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> combination is considered the first-line treatment for immunocompetent patients in East Africa [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/17\" class=\"abstract_t\">17</a>], based on results of a randomized trial in East Africa comparing three regimens: paromomycin (20 <span class=\"nowrap\">mg/kg/day</span> for 21 days), paromomycin 15 <span class=\"nowrap\">mg/kg/day</span> plus sodium stibogluconate 20 <span class=\"nowrap\">mg/kg/day</span> for 17 days, and sodium stibogluconate 20 <span class=\"nowrap\">mg/kg/day</span> for 30 days [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/21\" class=\"abstract_t\">21</a>]. The efficacy of paromomycin was significantly lower than sodium stibogluconate (84.3 versus 94.1 percent; difference 9.7 percent; 95% CI 3.6 to 15.7 percent). The efficacy of sodium stibogluconate plus paromomycin was comparable to sodium stibogluconate (91 versus 94 percent). The safety profile for the three treatment regimens was comparable. These data are a promising step in the shift to combination therapy.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Agents with activity against visceral leishmaniasis (VL) include amphotericin B, pentavalent antimonial drugs, <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a> (a parenteral aminoglycoside), and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> (the first oral drug for treatment of VL) (<a href=\"image.htm?imageKey=ID%2F80899\" class=\"graphic graphic_table graphicRef80899 \">table 2</a>). (See <a href=\"#H3\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liposomal amphotericin has the highest therapeutic efficacy and the most favorable safety profile for treatment of VL. We recommend treatment of VL with <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> in Europe, North America, and South America (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). However, sensitivity to specific drugs varies by region and first-line therapies in endemic areas. In India and Nepal, high-level resistance to antimonial drugs is common; in these regions, <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">miltefosine</a> and conventional or lipid-associated <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> have replaced antimonial drugs as first-line treatments. In East Africa, first-line therapy consists of combination treatment <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a> and <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a>. (See <a href=\"#H4029820504\" class=\"local\">'Overview'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is a broad consensus that antileishmanial therapy in endemic regions should move toward combination regimens to protect against development of drug resistance and to establish shorter treatment courses for improving compliance and reducing cost. (See <a href=\"#H2387204249\" class=\"local\">'Combination therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with VL should be evaluated for HIV coinfection; if found, HIV-VL coinfection should be treated aggressively with antiparasitic therapy and antiretroviral therapy. Following antiparasitic therapy, we suggest secondary prophylaxis to prevent relapses (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). In the absence of effective immune reconstitution, treatment response is poor in HIV-VL&ndash;coinfected patients. (See <a href=\"#H13\" class=\"local\">'HIV coinfection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VL infection in the setting of pregnancy has been associated with congenital infection and fetal death. We suggest <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> for treatment of VL in pregnancy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Alternative choices include <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> and pentavalent antimony. <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Miltefosine</a> is contraindicated in pregnancy. (See <a href=\"#H14\" class=\"local\">'Pregnancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Response to treatment is generally assessed clinically, based on resolution of fever, decrease in spleen size, and weight gain. Serologic tests are not useful tests of cure, as they remain positive for months to years after treatment. (See <a href=\"#H402494588\" class=\"local\">'Assessing response to treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of post kala-azar dermal leishmaniasis (PKDL) requires prolonged treatment; the optimal approach is uncertain and clinical trial data are limited. (See <a href=\"#H15\" class=\"local\">'Post kala-azar dermal leishmaniasis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) (2016). http://cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full.pdf+html (Accessed on November 16, 2016).</li><li class=\"breakAll\">Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.696.</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/3\" class=\"nounderline abstract_t\">Kuhls K, Keilonat L, Ochsenreither S, et al. Multilocus microsatellite typing (MLMT) reveals genetically isolated populations between and within the main endemic regions of visceral leishmaniasis. Microbes Infect 2007; 9:334.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/4\" class=\"nounderline abstract_t\">Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14:417.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/5\" class=\"nounderline abstract_t\">Sen Gupta PC. History of kala-azar in India. Indian Medical Gazette 1947; 82:281.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/6\" class=\"nounderline abstract_t\">Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/7\" class=\"nounderline abstract_t\">Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/8\" class=\"nounderline abstract_t\">Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97 Suppl 1:135.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/10\" class=\"nounderline abstract_t\">Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61:223.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/11\" class=\"nounderline abstract_t\">Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43:917.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/12\" class=\"nounderline abstract_t\">Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38:377.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/13\" class=\"nounderline abstract_t\">Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71:787.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/14\" class=\"nounderline abstract_t\">World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser 2010; :xii.</a></li><li class=\"breakAll\">US Food and Drug Administration. News and Events - FDA News Release. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm389671.htm (Accessed on March 24, 2014).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/16\" class=\"nounderline abstract_t\">Das VN, Siddiqui NA, Pandey K, et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk Manag 2009; 5:117.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/17\" class=\"nounderline abstract_t\">Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis 2016; 3:98.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/18\" class=\"nounderline abstract_t\">Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/19\" class=\"nounderline abstract_t\">Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003; 97:350.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/20\" class=\"nounderline abstract_t\">den Boer ML, Alvar J, Davidson RN, et al. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009; 14:395.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/21\" class=\"nounderline abstract_t\">Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) &amp; paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis 2012; 6:e1674.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/22\" class=\"nounderline abstract_t\">Musa AM, Younis B, Fadlalla A, et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 2010; 4:e855.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/23\" class=\"nounderline abstract_t\">Khalil EA, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis 2014; 8:e2613.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/24\" class=\"nounderline abstract_t\">Wasunna M, Njenga S, Balasegaram M, et al. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLoS Negl Trop Dis 2016; 10:e0004880.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/25\" class=\"nounderline abstract_t\">Olivier M, Badar&oacute; R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97 Suppl 1:79.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/26\" class=\"nounderline abstract_t\">Tremblay M, Olivier M, Bernier R. Leishmania and the pathogenesis of HIV infection. Parasitol Today 1996; 12:257.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/27\" class=\"nounderline abstract_t\">van Griensven J, Carrillo E, L&oacute;pez-V&eacute;lez R, et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014; 20:286.</a></li><li class=\"breakAll\">World Health Organization, 2007. Report of the 5th Consultative Meeting on Leishmania/HIV Coinfection. WHO Technical Report Series WHO/CDS/NTD/IDM/2007.5.</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/29\" class=\"nounderline abstract_t\">ter Horst R, Collin SM, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/30\" class=\"nounderline abstract_t\">Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 2013; 7:e2195.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/31\" class=\"nounderline abstract_t\">Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87:75.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/32\" class=\"nounderline abstract_t\">Laguna F, L&oacute;pez-V&eacute;lez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13:1063.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/33\" class=\"nounderline abstract_t\">Laguna F, Videla S, Jim&eacute;nez-Mej&iacute;as ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003; 52:464.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/34\" class=\"nounderline abstract_t\">Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32:133.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/35\" class=\"nounderline abstract_t\">Lazanas MC, Tsekes GA, Papandreou S, et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/36\" class=\"nounderline abstract_t\">Torre-Cisneros J, Villanueva JL, Kindelan JM, et al. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17:625.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/37\" class=\"nounderline abstract_t\">Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/38\" class=\"nounderline abstract_t\">Sudarshan M, Weirather JL, Wilson ME, Sundar S. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother 2011; 66:1751.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/39\" class=\"nounderline abstract_t\">Laguna F, Torre-Cisneros J, Moreno V, et al. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:711.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/40\" class=\"nounderline abstract_t\">Sindermann H, Engel KR, Fischer C, et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39:1520.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/41\" class=\"nounderline abstract_t\">Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/42\" class=\"nounderline abstract_t\">Delgado J, Mac&iacute;as J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 1999; 61:766.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/43\" class=\"nounderline abstract_t\">Monge-Maillo B, L&oacute;pez-V&eacute;lez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis 2015; 60:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/44\" class=\"nounderline abstract_t\">Mahajan R, Das P, Isaakidis P, et al. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clin Infect Dis 2015; 61:1255.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/45\" class=\"nounderline abstract_t\">Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis 2014; 8:e3053.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/46\" class=\"nounderline abstract_t\">Diro E, Lynen L, Ritmeijer K, et al. Visceral Leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis 2014; 8:e2869.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/47\" class=\"nounderline abstract_t\">Alvar J, Ca&ntilde;avate C, Guti&eacute;rrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/48\" class=\"nounderline abstract_t\">Ribera E, Oca&ntilde;a I, de Otero J, et al. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100:496.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/49\" class=\"nounderline abstract_t\">Pintado V, Mart&iacute;n-Rabad&aacute;n P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80:54.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/50\" class=\"nounderline abstract_t\">de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32:633.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/51\" class=\"nounderline abstract_t\">Tortajada C, P&eacute;rez-Cuevas B, Moreno A, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:364.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/52\" class=\"nounderline abstract_t\">Abongomera C, Diro E, Vogt F, et al. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study. Clin Infect Dis 2017; 65:1703.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/53\" class=\"nounderline abstract_t\">L&oacute;pez-V&eacute;lez R, Videla S, M&aacute;rquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/54\" class=\"nounderline abstract_t\">Mira JA, Corzo JE, Rivero A, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70:298.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/55\" class=\"nounderline abstract_t\">Casado JL, Lopez-Velez R, Pintado V, et al. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20:202.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/56\" class=\"nounderline abstract_t\">Diro E, Ritmeijer K, Boelaert M, et al. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study. PLoS Negl Trop Dis 2015; 9:e0004087.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/57\" class=\"nounderline abstract_t\">Meinecke CK, Schottelius J, Oskam L, Fleischer B. Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. Pediatrics 1999; 104:e65.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/58\" class=\"nounderline abstract_t\">Gradoni L, Gaeta GB, Pellizzer G, et al. Mediterranean visceral leishmaniasis in pregnancy. Scand J Infect Dis 1994; 26:627.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/59\" class=\"nounderline abstract_t\">Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/60\" class=\"nounderline abstract_t\">Utili R, Rambaldi A, Tripodi MF, Andreana A. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate. Infection 1995; 23:182.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/61\" class=\"nounderline abstract_t\">Sundar S, Sinha P, Jha TK, et al. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health 2013; 18:96.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/62\" class=\"nounderline abstract_t\">Ghosh S, Das NK, Mukherjee S, et al. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis. Am J Trop Med Hyg 2015; 93:767.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/63\" class=\"nounderline abstract_t\">Ramesh V, Singh R, Avishek K, et al. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. PLoS Negl Trop Dis 2015; 9:e0004093.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/64\" class=\"nounderline abstract_t\">Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/65\" class=\"nounderline abstract_t\">Thakur CP, Kumar K, Sinha PK, et al. Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. Br Med J (Clin Res Ed) 1987; 295:886.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/66\" class=\"nounderline abstract_t\">Thakur CP, Narain S, Kumar N, et al. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997; 91:611.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/67\" class=\"nounderline abstract_t\">Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005; 99:563.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/68\" class=\"nounderline abstract_t\">Abongomera C, Gatluak F, Buyze J, Ritmeijer K. A Comparison of the Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe Post Kala Azar Dermal Leishmaniasis in South Sudan - A Retrospective Cohort Study. PLoS One 2016; 11:e0163047.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/69\" class=\"nounderline abstract_t\">Burza S, Sinha PK, Mahajan R, et al. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 2014; 8:e2603.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/70\" class=\"nounderline abstract_t\">Bern C, Haque R, Chowdhury R, et al. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg 2007; 76:909.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/71\" class=\"nounderline abstract_t\">Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/72\" class=\"nounderline abstract_t\">Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 2008; 102:32.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/73\" class=\"nounderline abstract_t\">Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002; 8:319.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/74\" class=\"nounderline abstract_t\">Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 Suppl 1:21.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/75\" class=\"nounderline abstract_t\">Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4:179.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/76\" class=\"nounderline abstract_t\">Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/77\" class=\"nounderline abstract_t\">di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131:271.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/78\" class=\"nounderline abstract_t\">Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36:560.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/79\" class=\"nounderline abstract_t\">Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/80\" class=\"nounderline abstract_t\">Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124:664.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/81\" class=\"nounderline abstract_t\">Sundar S, Jha TK, Thakur CP, et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/82\" class=\"nounderline abstract_t\">Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001; 17:67.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/83\" class=\"nounderline abstract_t\">Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90:319.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/84\" class=\"nounderline abstract_t\">Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 2003; 9:1617.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/85\" class=\"nounderline abstract_t\">Kafetzis DA, Velissariou IM, Stabouli S, et al. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005; 25:26.</a></li><li class=\"breakAll\">World Health Organization. WHO and Gilead sign agreement for enhanced access to visceral leishmaniasis treatment. http://www.who.int/neglected_diseases/Gilead_donation_2011/en/ (Accessed on May 15, 2014).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/87\" class=\"nounderline abstract_t\">Sundar S, Jha TK, Thakur CP, et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37:800.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/88\" class=\"nounderline abstract_t\">Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504.</a></li><li class=\"breakAll\">World Health Organization. Report of a WHO Informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis, Rome, Italy, April 2005. WHO/CDS/NTD/IDM/2007.4 Geneva: WHO, 2007.</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/90\" class=\"nounderline abstract_t\">Mondal D, Alvar J, Hasnain MG, et al. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health 2014; 2:e51.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/91\" class=\"nounderline abstract_t\">Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/92\" class=\"nounderline abstract_t\">Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007; 45:556.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/93\" class=\"nounderline abstract_t\">Gaeta GB, Maisto A, Di Caprio D, et al. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J Infect Dis 2000; 32:675.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/94\" class=\"nounderline abstract_t\">Sundar S, Mehta H, Chhabra A, et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 2006; 42:608.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/95\" class=\"nounderline abstract_t\">Sundar S, Singh A, Agarwal D, et al. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 2009; 80:700.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/96\" class=\"nounderline abstract_t\">den Boer M, Davidson RN. Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 2006; 4:187.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/97\" class=\"nounderline abstract_t\">Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5:312.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/98\" class=\"nounderline abstract_t\">Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79:388.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/99\" class=\"nounderline abstract_t\">Rijal S, Chappuis F, Singh R, et al. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 2003; 97:597.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/100\" class=\"nounderline abstract_t\">Sundar S, Sinha PR, Agrawal NK, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998; 59:139.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/101\" class=\"nounderline abstract_t\">Fr&eacute;zard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009; 14:2317.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/102\" class=\"nounderline abstract_t\">Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. J Med Chem 2009; 52:2603.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/103\" class=\"nounderline abstract_t\">Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/104\" class=\"nounderline abstract_t\">Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34:702.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/105\" class=\"nounderline abstract_t\">Gasser RA Jr, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/106\" class=\"nounderline abstract_t\">Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/107\" class=\"nounderline abstract_t\">Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention: Parasites - Leishmaniasis http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl (Accessed on March 25, 2014).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/109\" class=\"nounderline abstract_t\">Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/110\" class=\"nounderline abstract_t\">Sundar S, Jha TK, Sindermann H, et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/111\" class=\"nounderline abstract_t\">Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007; 196:591.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/112\" class=\"nounderline abstract_t\">Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 2013; 56:1530.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/113\" class=\"nounderline abstract_t\">Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55:543.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/114\" class=\"nounderline abstract_t\">Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 2012; 56:3864.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/115\" class=\"nounderline abstract_t\">Dorlo TP, Rijal S, Ostyn B, et al. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis 2014; 210:146.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/116\" class=\"nounderline abstract_t\">Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1:S26.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/117\" class=\"nounderline abstract_t\">Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005; 83:394.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/118\" class=\"nounderline abstract_t\">Pandey BD, Pandey K, Kaneko O, et al. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg 2009; 80:580.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/119\" class=\"nounderline abstract_t\">Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009; 103:653.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/120\" class=\"nounderline abstract_t\">Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316:1200.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/121\" class=\"nounderline abstract_t\">Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007; 356:2571.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/122\" class=\"nounderline abstract_t\">Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:429.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/123\" class=\"nounderline abstract_t\">Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84:221.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/124\" class=\"nounderline abstract_t\">Melaku Y, Collin SM, Keus K, et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007; 77:89.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/125\" class=\"nounderline abstract_t\">Jhingran A, Chawla B, Saxena S, et al. Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 2009; 164:111.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/126\" class=\"nounderline abstract_t\">Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/127\" class=\"nounderline abstract_t\">Seaman J, Pryce D, Sondorp HE, et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168:715.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/128\" class=\"nounderline abstract_t\">Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-treatment/abstract/129\" class=\"nounderline abstract_t\">Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377:477.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5710 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">GENERAL PRINCIPLES</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL APPROACH</a><ul><li><a href=\"#H4029820504\" id=\"outline-link-H4029820504\">Overview</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Special circumstances</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- HIV coinfection</a><ul><li><a href=\"#H289398907\" id=\"outline-link-H289398907\">Antiparasitic therapy</a></li><li><a href=\"#H487906761\" id=\"outline-link-H487906761\">Antiretroviral therapy</a></li><li><a href=\"#H1083951617\" id=\"outline-link-H1083951617\">Secondary prophylaxis</a></li></ul></li><li><a href=\"#H2377420657\" id=\"outline-link-H2377420657\">- Other immunocompromised hosts</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Pregnancy</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Post kala-azar dermal leishmaniasis</a></li></ul></li><li><a href=\"#H402494588\" id=\"outline-link-H402494588\">Assessing response to treatment</a></li><li><a href=\"#H2154256700\" id=\"outline-link-H2154256700\">Adjusting therapy</a></li></ul></li><li><a href=\"#H3201726250\" id=\"outline-link-H3201726250\">THERAPEUTIC AGENTS</a><ul><li><a href=\"#H4029043717\" id=\"outline-link-H4029043717\">Amphotericin B</a><ul><li><a href=\"#H518134611\" id=\"outline-link-H518134611\">- Liposomal</a></li><li><a href=\"#H378131154\" id=\"outline-link-H378131154\">- Conventional</a></li><li><a href=\"#H1386914187\" id=\"outline-link-H1386914187\">- Other preparations</a></li></ul></li><li><a href=\"#H337115261\" id=\"outline-link-H337115261\">Pentavalent antimonial compounds</a></li><li><a href=\"#H2348435053\" id=\"outline-link-H2348435053\">Miltefosine</a></li><li><a href=\"#H2940407862\" id=\"outline-link-H2940407862\">Paromomycin</a></li><li><a href=\"#H2387204249\" id=\"outline-link-H2387204249\">Combination therapy</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5710|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/58861\" class=\"graphic graphic_table\">- Leishmaniasis species</a></li><li><a href=\"image.htm?imageKey=ID/80899\" class=\"graphic graphic_table\">- Treatment of visceral leishmaniasis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient</a></li></ul></div></div>","javascript":null}